More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Small molecules remain the dominant modality in pharmaceuticals based on approvals of new molecular entities (NMEs), but biologics continue to make inroads. So what do the numbers show? Small molecules accounted for nearly three-fourths of NME...

A recent study from Accenture and HFS Research points to the need to have “intelligent operations” to drive business outcomes. So what is a winning approach for “intelligent operations?” The study surveyed nearly 500 executives to analyze the...

Policymakers and the biopharmaceutical industry have been discussing the opportunity of biosimilars for more than a decade, but where do biosimilars stand today? The opportunities loom larger than ever today, with about $100 billion worth of...

Which executives and other leaders may have the largest impact for the pharmaceutical industry in 2018? DCAT Value Chain Insights offers a top ten ranking. Which executives should be on your radar in 2018? DCAT Value Chain Insights examines some...

So what is on the minds of CEOs? PwC’s annual study released this week at the World Economic Forum in Davos, Switzerland shows a record-breaking level of optimism among CEOs about global economic prospects, at least in the short term. So what did...

Retail medicine spending in the US grew only 1.3% in 2016, down from 9% in 2015, according to a recent analysis by the US Centers for Medicare & Medicaid Services, which annually produces projections of healthcare spending in the US. So how...

Jim Miller is founder and president of PharmSource, a GlobalData company, a provider of market intelligence on the contract drug development and manufacturing industry. The year 2017 was a strong one for the CDMO industry with growth of 10% or...

What will be the key trends shaping the pharmaceutical industry in 2018? DCAT Value Chain Insights takes an inside look. From increased mergers and acquisitions (M&A), driven in part by US tax reform, to continued strength in venture capital...

The US Food and Drug Administration (FDA) approved 46 new molecular entities (NMEs) in 2017, more than double the number approved in 2016 and a 21-year high. So which drugs made the mark? Following a downturn in 2016 when only 22 NME were...